- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ENZYMATICA Aktie jetzt für 0€ handeln | |||||
| Do | Enzymatica AB: Bulletin from annual general meeting of Enzymatica AB (publ) on 7 May 2026 | 142 | GlobeNewswire (Europe) | The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
Enzymatica AB (publ) held its annual... ► Artikel lesen | |
| 28.04. | Enzymatica AB: Quarterly report Q1/2026 - Enzymatica strengthens international position through STADA agreement | 396 | GlobeNewswire (Europe) | First quarter
Net sales amounted to SEK 11.4 million (12.3).
Operating result amounted to SEK -13.6.million (-18.0)
Earnings per share, before... ► Artikel lesen | |
| 14.04. | ENZYMATICA AB: Enzymatica publishes annual report for 2025 | 1 | Cision News | ||
| 31.03. | Enzymatica AB: Enzymatica and STADA sign partnership agreement for Germany and Austria | 409 | GlobeNewswire (Europe) | Regulatory press release
• The new partnership agreement covers the launch and distribution of Enzymatica's ColdZyme® technology in oral spray form in Germany and Austria
• The partnership combines... ► Artikel lesen | |
| 31.03. | Notice of Annual General Meeting 2026 in Enzymatica AB (publ) | 4 | Cision News | ||
| 18.02. | Enzymatica AB: Year-end report 2025: New CEO takes the helm - initiates the next phase of Enzymatica's international expansion | 391 | PR Newswire | LUND, Sweden, Feb. 18, 2026 /PRNewswire/ --
Fourth quarterJanuary-December
Net sales reached SEK 18.3 (17.2) millionThe operating result totaled SEK -10.2 (-13.7) million.Earnings... ► Artikel lesen | |
| 11.12.25 | Enzymatica AB: Enzymatica appoints Acting CFO during transition period | 186 | GlobeNewswire (Europe) | Enzymatica today announces the appointment of Kristina Rylander as Acting CFO during a transition period in the spring of 2026. She will assume the role on 1 March 2026, following the departure of the... ► Artikel lesen | |
| 20.11.25 | Enzymatica AB: Enzymatica enters partnership with the UK Sports Institute to support athlete health and performance | 237 | GlobeNewswire (Europe) | ColdZyme, the mouth spray developed by Enzymatica AB, has entered into a new partnership with the UK Sports Institute (UKSI) to support the institute's work in promoting athlete health and wellbeing.
The... ► Artikel lesen | |
| 30.10.25 | Enzymatica AB: Quarterly report Q3/2025: Strong development in Sweden and continued focus on international expansion | 336 | PR Newswire | LUND, Sweden, Oct. 30, 2025 /PRNewswire/ --
Third quarter
January-September
... ► Artikel lesen | |
| 13.10.25 | Enzymatica AB: Enzymatica appoints Holger Lembrér as new CFO | 355 | GlobeNewswire (Europe) | Enzymatica AB (publ) has appointed Holger Lembrér as new Chief Financial Officer (CFO). He will assume the position no later than April 2026 and will be part of the company's executive management team.
Holger... ► Artikel lesen | |
| 01.10.25 | Enzymatica AB: Enzymatica to Support Swedish Biathlon Federation as Official Supplier | 219 | GlobeNewswire (Europe) | Enzymatica is proud to announce a partnership with the Swedish Biathlon Federation, under which Enzymatica becomes an Official Supplier to the national federation.
The collaboration focuses on initiatives... ► Artikel lesen | |
| 22.08.25 | Enzymatica AB: Bulletin from the Extraordinary General Meeting of Enzymatica AB (publ) on 22 August 2025 | 229 | GlobeNewswire (Europe) | On 22 August 2025, the shareholders of Enzymatica AB (publ) (the "Company") held an Extraordinary General Meeting. The following principal resolutions were adopted at the Meeting.
Election of Board... ► Artikel lesen | |
| 12.08.25 | Enzymatica AB: Sana Alajmovic appointed new CEO of Enzymatica AB | 365 | GlobeNewswire (Europe) | The Board of Directors of Enzymatica AB (publ) has appointed Sana Alajmovic as the new Chief Executive Officer. She succeeds Claus Egstrand, who has announced that he is stepping down from his operational... ► Artikel lesen | |
| 17.07.25 | Quarterly report Q2/2025: Strong development in Sweden and increased international activity: Enzymatica AB | 462 | PR Newswire | LUND, Sweden, July 17, 2025
/PRNewswire/ --
Second quarter
Net sales reached SEK 8.3 (6.4) million.The operating result totaled SEK -14.9 (-13.5) million.Earnings per... ► Artikel lesen | |
| 30.06.25 | Enzymatica AB: Enzymatica's CFO Therese Filmersson to leave her position | 229 | GlobeNewswire (Europe) | Enzymatica AB (publ) announces today that the company's Chief Financial Officer (CFO), Therese Filmersson, has decided to leave her position. The decision has been made in mutual agreement between Therese... ► Artikel lesen | |
| 26.06.25 | Enzymatica AB: Claus Egstrand steps down as CEO of Enzymatica | 457 | GlobeNewswire (Europe) | The CEO of Enzymatica AB, Claus Egstrand, is stepping down from his role and will join the company's Board of Directors. Recruitment of a new CEO has begun. The change will ensure long-term stability... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 38,440 | +3,67 % | Bayer zahlt bis zu 2,45 Milliarden Dollar für Übernahme im Bereich Augenheilkunde | Der DAX-notierte Bayer-Konzern übernimmt Perfuse Therapeutics vollständig und sichert sich damit die weltweiten Rechte an PER-001, einem niedermolekularen Endothelinrezeptor-Antagonisten in der klinischen... ► Artikel lesen | |
| NOVO NORDISK | 39,655 | -0,51 % | Novo-Nordisk-Aktie: Geht jetzt plötzlich alles ganz schnell? | Über Wochen und Monate hinweg war die Aktie von Novo Nordisk abgemeldet. Jetzt blickt sie auf ein bemerkenswertes Comeback zurück. Kann dieses anhalten? Novo Nordisk nach den Zahlen: Spürbare Erleichterung!... ► Artikel lesen | |
| PFIZER | 22,040 | -0,05 % | Dividendenbekanntmachungen (08.05.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADDNODE GROUP AB SE0017885767 1,15 SEK 0,1057 EUR ADIDAS AG DE000A1EWWW0 - 2,8 EUR ALLIANCE RESOURCE PARTNERS LP US01877R1086 0... ► Artikel lesen | |
| GILEAD SCIENCES | 115,06 | +0,09 % | Gilead: Erwartungen übertroffen - darum fällt die Aktie trotzdem | Die Biotech-Gesellschaft Gilead Sciences hat am Donnerstagabend nach US-Börsenschluss die Zahlen für das erste Quartal des neuen Geschäftsjahres veröffentlicht. Trotz besser als erwarteter Vorgaben... ► Artikel lesen | |
| SANOFI | 73,47 | +0,10 % | Mesoblast Aktie: Warum sich der Blick auf diesen Biotech-Player jetzt lohnt - und was Anleger von Merck, Regeneron & Co. lernen können | ||
| GSK | 21,790 | +2,06 % | GSK findet für neues Hepatitis-Medikament Vertriebspartner in China | DJ GSK findet für neues Hepatitis-Medikament Vertriebspartner in China
Von Adria Calatayud
DOW JONES--GSK kooperiert mit Sino Biopharmaceutical, um die Markteinführung für sein Hepatitis-B-Medikament... ► Artikel lesen | |
| ABBVIE | 177,45 | +0,20 % | Ihre wichtigsten Termine: Heute im Fokus: AbbVie, Colgate-Palmolive, Toyota, Sony, Krones, Bechtle, Evonik | © Foto: Hiro Komae/AP/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 05:00... ► Artikel lesen | |
| CANOPY GROWTH | 0,940 | +0,94 % | CANOPY GROWTH CORPORATION: Struktur vor Impuls | ||
| STADA ARZNEIMITTEL | - | - | Enzymatica AB: Quarterly report Q1/2026 - Enzymatica strengthens international position through STADA agreement | First quarter
Net sales amounted to SEK 11.4 million (12.3).
Operating result amounted to SEK -13.6.million (-18.0)
Earnings per share, before... ► Artikel lesen | |
| ASTRAZENECA | 157,35 | +0,10 % | AstraZeneca und OMP demonstrieren auf dem Gartner Supply Chain Symposium/Xpo 2026 Planung im Tempo des Wandels | Wie eine schnelle Entscheidungsfindung die Lücke zwischen Erkenntnis und Handeln in komplexen, schnelllebigen Lieferketten
schließt
ANTWERPEN, BE / ACCESS Newswire / 7. Mai 2026... ► Artikel lesen | |
| INNOCAN PHARMA | 3,220 | 0,00 % | Breaking News: Schmerzfrei ohne Nebenwirkung?! - Fachblatt berichtet! | ||
| CRONOS GROUP | 2,330 | -1,10 % | Cronos Group Inc.: Cronos Group Reports 2026 First Quarter Results | Net revenue in Q1 2026 increased by 40% year-over-year to $45.2 million Achieved record net revenue and gross profit in Q1 2026 Reached #1 market share in vapes in Canada1 Ninth consecutive quarter... ► Artikel lesen | |
| VIATRIS | 14,594 | -0,36 % | Viatris Swings To Q1 Profit, Reaffirms FY26 Outlook | WASHINGTON (dpa-AFX) - Viatris Inc. (VTRS), a healthcare company, Thursday reported earnings for the first quarter compared to a loss for the same period last year. The results particularly... ► Artikel lesen | |
| HAEMATO | 12,000 | -4,00 % | M1 Kliniken schließt Verkauf von Haemato Pharm ab | Die M1 Kliniken AG hat den Verkauf der Haemato Pharm GmbH über ihre Mehrheitsbeteiligung Haemato AG an die Phoenix Group mit Wirkung zum Ablauf des 31. Januar 2026 abgeschlossen. Sämtliche Vollzugsbedingungen... ► Artikel lesen | |
| SINOPHARM | 2,030 | +0,40 % | Reed Sinopharm Exhibitions (RSE): PCHi 2026: World's Largest Cosmetics Ingredients Exhibition Opens in Hangzhou | 860+ exhibitors from 26 countries and regions across 70,000 sqmClose to 50 new product launches, including global and China debuts295 product submissions and 19 engineer nominations for the... ► Artikel lesen |
ENZYMATICA AB gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,235 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ENZYMATICA AB finden Sie auf Wallstreet Online.